REPUBLICHC(08357) - 2022 Q2 - 季度财报

Announcement Overview This section provides an overview of the supplementary announcement by Republic Healthcare Limited Purpose and Background of the Announcement This supplementary announcement from Republic Healthcare Limited details the segmented use of proceeds from its share offer and placement, supplementing the aggregated disclosure in the 2022 interim report - This announcement supplements Republic Healthcare Limited's interim results announcement and interim report dated August 5, 2022[3] - The announcement aims to provide a segmented report on the use of proceeds from the share offer and placement, previously reported in aggregate in the interim report[3] Use of Proceeds from Share Offer and Placement This section details the allocation and utilization of proceeds from both the share offer and placement Details of Use of Proceeds from Share Offer As of June 30, 2022, the company utilized S$6,627 thousand from the share offer proceeds, primarily for talent acquisition and DTAP clinic network expansion, with S$2,473 thousand remaining for H2 FY2023 - The total original and revised allocation of share offer proceeds was S$9,100 thousand[3] - As of June 30, 2022, S$6,627 thousand was utilized, with a balance of S$2,473 thousand remaining[3] Details of Use of Proceeds from Share Offer (As of June 30, 2022) | Purpose | Original Allocation (S$ '000) | Revised Allocation (S$ '000) | Actual Utilization as of June 30, 2022 (S$ '000) | Balance as of June 30, 2022 (S$ '000) | Expected Timeline for Utilizing Unused Balance | | :--- | :--- | :--- | :--- | :--- | :--- | | Strategically expanding and strengthening the DTAP clinic network | 2,600 | 2,031 | 1,731 | 300 | H2 FY2023 | | Opening new SA clinics | 1,400 | 1,220 | 1,220 | — | N/A | | Continuous recruitment and retention of medical and staff talent | 4,300 | 4,376 | 3,176 | 1,200 | H2 FY2023 | | Enhancing and improving IT infrastructure and systems | 600 | 400 | 400 | — | N/A | | Establishing a central pharmacy | 100 | — | — | — | N/A | | General working capital | 100 | 100 | 100 | — | N/A | | Pepper trading business | — | 250 | — | 250 | H2 FY2022 | | Healthcare-related education business | — | 480 | — | 480 | H2 FY2022 | | Existing clinic operations | — | 243 | — | 243 | H2 FY2022 | | Total (A) | 9,100 | 9,100 | 6,627 | 2,473 | | Details of Use of Proceeds from Placement As of June 30, 2022, the S$3,600 thousand proceeds from the placement remain unutilized, earmarked for new online DTAP business, potential acquisitions, and allied health services, with utilization expected from H2 2023 to H1 2024 - The total placement proceeds amounted to S$3,600 thousand, with no actual utilization and a balance of S$3,600 thousand as of June 30, 2022[5] Details of Use of Proceeds from Placement (As of June 30, 2022) | Purpose | Original Allocation (S$ '000) | Revised Allocation (S$ '000) | Actual Utilization as of June 30, 2022 (S$ '000) | Balance as of June 30, 2022 (S$ '000) | Expected Timeline for Utilizing Unused Balance | | :--- | :--- | :--- | :--- | :--- | :--- | | Establishing a new online business branch for DTAP | 600 | 600 | — | 600 | H2 2023 | | Acquiring a potential corporate interest | 500 | 500 | — | 500 | H2 2023 | | Allied health and/or provision of ancillary healthcare products and services | 1,000 | 1,000 | — | 1,000 | H1 2024 | | General working capital | 1,500 | 1,500 | — | 1,500 | N/A | | Total (B) | 3,600 | 3,600 | — | 3,600 | | Total and Unutilized Balance The combined proceeds from the share offer and placement total S$12,700 thousand, with S$6,627 thousand utilized and S$6,073 thousand remaining unutilized as of June 30, 2022 Total Proceeds from Share Offer and Placement (As of June 30, 2022) | Metric | Amount (S$ '000) | | :--- | :--- | | Total ((A) + (B)) | 12,700 | | Actual Utilization as of June 30, 2022 | 6,627 | | Balance as of June 30, 2022 | 6,073 | Other Information This section covers the board's confirmation of the interim report's unchanged information and the publication details of this announcement Board Confirmation and Publication The Board confirms all other information in the 2022 interim report remains unchanged and assumes full responsibility for the accuracy and completeness of this announcement, which will be published on the GEM and company websites - The Board confirms that all other information in the 2022 interim report remains unchanged[5] - The Board members collectively and individually assume full responsibility for the accuracy, completeness, and absence of misleading or fraudulent content in this announcement[6] - This announcement will be published on the GEM website (www.hkgem.com) and the company website (republichealthcare.asia) for at least seven days[6]